Smart Automation for iPSC
Revolutionizing regenerative medicine through automated induced pluripotent stem cell (iPSC) technology.
Lumistar's modular iPSC automation system, co-developed with Panasonic, enhances stability, efficiency, and scalability in cell reprogramming and differentiation. Integrated with high-throughput imaging and real-time detection, it accelerates drug discovery and clinical-grade cell therapy development. Aivita Health Group collaborates closely with Lumistar to advance the application of this cutting-edge technology in regenerative healthcare.
- Automated iPSC cultivation and differentiation
- GTP-compliant modular cell processing
- Disease modeling for neurodegenerative disorders
- High-content screening for drug discovery
Middle East Cell Bank Initiative
Pioneering a regional biorepository for regenerative medicine and precision healthcare.
Led by Aivita Health Group, the Middle East Cell Bank aims to establish a GMP-compliant, regionally integrated platform for clinical-grade iPSC, MSC, and exosome storage and distribution. Designed to support advanced therapies, personalized medicine, and cross-border research collaboration.
👉 Empowering the future of cell-based therapies across the MENA region.
- Clinical-grade iPSC, MSC, and exosome storage
- GMP-compliant bioprocessing protocols
- Cross-border research and therapy support
- Scalable infrastructure for MENA healthcare
AI-Driven Health Database
Secure, intelligent personal health database integrated with AI-powered decision support for enhanced clinical efficiency.
Combines smart data integration, timeline visualization, and AI-driven recommendations to assist physicians in making accurate, timely decisions.
- Multimodal health data aggregation
- RAG-based report summarization
- Clinical decision support system
- HIPAA/GDPR-compliant infrastructure
Latest Research Results
Exosome Quality Assessment – Standardized and quantitative exosome QC technology designed for therapeutic-grade consistency.
Our platform evaluates critical quality metrics—including particle size (30–150 nm), surface/internal markers, Annexin V negativity, and functional EGF/VEGF protein levels—to ensure treatment-grade purity and potency.
- Size verification within therapeutic range (30–150 nm)
- Surface/internal marker validation (CD9/CD63/CD81, TSG101, Alix)
- Annexin V negativity check to rule out apoptotic-body contamination
- Functional protein assays: EGF & VEGF quantification